Tirofiban counteracts endothelial cell apoptosis through the VEGF/VEGFR2/pAkt axis

Vascular Pharmacology

Volumn 80, Issue , 2016, Pages 67-74

  Giordano, Arturo ^a   Romano, Simona ^b   D'Angelillo, Anna ^b   Corcione, Nicola ^a   Messina, Stefano ^a   Avellino, Raffaella ^a   Biondi Zoccai, Giuseppe ^c   Ferraro, Paolo ^a   Romano, Maria Fiammetta ^b  

^a Pineta Grande Hospital   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Apoptosis; Endothelial; RGD mimetic; VEGF

Indexed keywords

BIM PROTEIN; CASPASE 3; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACTOLISIB; EGTAZIC ACID; PROTEIN BAK; PROTEIN KINASE B; TIROFIBAN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; BETA3 INTEGRIN; KDR PROTEIN, HUMAN; TUMOR NECROSIS FACTOR; TYROSINE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE TECHNIQUE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM;

APOPTOSIS; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL SURVIVAL; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTEGRIN BETA3; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84951753112     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.12.001     Document Type: Article

References (27)

1. Hartman G.D., Egbertson M.S., Halczenko W., Laswell W.L., Duggan M.E., Smith R.L., et al. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. 1992, 35:4640-4642.
2. Bledzka K., Smyth S.S., Plow E.F. Integrin αIIbβ3: from discovery to efficacious therapeutic target. Circ. Res. 2013, 112:1189-1200.
3. Bennett J.S. Structure and function of the platelet integrin alphaIIbbeta3. J. Clin. Invest. 2005, 115:3363-3369.
4. Ruoslahti E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 1996, 12:697-715.
5. Giordano A., D'Angelillo A., Romano S., D'Arrigo P., Corcione N., Bisogni R., et al. Tirofiban induces VEGF production and stimulates migration and proliferation of endothelial cells. Vasc. Pharmacol. 2014, 61:63-71.
6. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998, 273:30336-30343.
7. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 2003, 3:745-756. 10.1038/nri1184.
8. Zhou Z., Lauer M.A., Wang K., Forudi F., Zhou X., Song X., et al. Effect of anti-tumor necrosis factor-α polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. Atherosclerosis 2002, 16:153-159.
9. Kim H., Rafiuddin-Shah M., Tu H.C., Jeffers J.R., Zambetti G.P., Hsieh J.J., et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 2006, 8:1348-1358.
10. Giordano A., Romano S., Nappo G., Messina S., Polimeno M., Corcione N., et al. Atorvastatin sensitises vascular smooth muscle cells, but not endothelial cells, to TNF-α-induced cell death. Curr. Pharm. Des. 2012, 18:6331-6338.
11. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
12. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin avb3 for angiogenesis. Science 1994, 264:569-571.
13. Romano S., D'Angelillo A., Staibano S., Simeone E., D'Arrigo P., Ascierto P.A., et al. Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients. Pigment Cell Melanoma Res. 2015, 28:442-452. 10.1111/pcmr.12378.
14. Gristina A.G., Giridhar G., Gabriel B.L., Naylor P.T., Myrvik Q.N. Cell biology and molecular mechanisms in artificial device infections. Int. J. Artif. Organs 1993, 16:755-763.
15. Xiong J.P., Stehle T., Diefenbach B., Zhang R., Dunker R., Scott D.L., et al. Crystal structure of the extra-cellular segment of integrin alpha Vbeta3. Science 2001, 294:339-345.
16. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7:359-371.
17. Maira S.M., Stauffer F., Schnell C., García-Echeverría C. PI3K inhibitors for cancer treatment: where do we stand?. Biochem. Soc. Trans. 2009, 37:265-272. 10.1042/BST0370265.
18. Durand E., Scoazec A., Lafont A., Boddaert J., Al Hajzen A., Addad F., et al. In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion. Circulation 2004, 109:2503-2506.
19. Hantgan R.R., Paumi C., Rocco M., Weisel J.W. Effects of ligand-mimetic peptides Arg-Gly-Asp-X (X = Phe, Trp, Ser) on alphaIIbbeta3 integrin conformation and oligomerization. Biochemistry 1999, 38:14461-14474.
20. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996, 274:787-789.
21. Marques-Fernandez F., Planells-Ferrer L., Gozzelino R., Galenkamp K.M.O., Reix S., Llecha-Cano N., et al. TNFα induces survival through the FLIP-L-dependent activation of the MAPK/ERK pathway. Cell Death Dis. 2013, 4. 10.1038/cddis.2013.25.
22. Luo H., Yang Y., Duan J., Wu P., Jiang Q., Xu C. PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells. Cell Death Dis. 2013, 4:481. 10.1038/cddis.2013.3.
23. Buckley C.D., Pilling D., Henriquez N.V., Parsonage G., Threlfall K., Scheel-Toellner D., et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature 1999, 397:534-539.
24. Adderley S.R., Fitzgerald D.J. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J. Biol. Chem. 2000, 275:5760-5766.
25. Leytin V., Mutlu A., Mykhaylov S., Allen D.J., Gyulkhandanyan A.V., Freedman J. The GPIIbIIIa antagonist drugs eptifibatide and tirofiban do not induce activation of apoptosis executioner caspase-3 in resting platelets but inhibit caspase-3 activation in platelets stimulated with thrombin or calcium ionophore A23187. Haematologica 2009, 94:1783-1784.
26. Schneider D.J., Herrmann H.C., Lakkis N., Aguirre F., Lo M.W., Yin K.C., et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am. J. Cardiol. 2003, 91:334-336.
27. Moser M., Bertram U., Peter K., Bode C., Ruef J. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J. Cardiovasc. Pharmacol. 2003, 41:586-592.